Bleeding News and Research

RSS

GFAP levels predict brain injury, death in critically ill children on ECMO

Johns Hopkins Children's Center scientists have discovered that high blood levels of a protein commonly found in the central nervous system can predict brain injury and death in critically ill children on a form of life support called extra-corporeal membrane oxygenation or ECMO.

23 Nov 2010

Military surgeons provide guidance on handling emergency blast injuries

Hospitals all over the world need to be aware of how to treat emergency blast injuries and military surgeons can provide valuable knowledge and advice to their civilian counterparts based on their experience of battlefield injuries. That is the driving force behind two papers published online by BJS, the British Journal of Surgery.

22 Nov 2010

CSU invents artificial body parts that look, feel, behave, and bleed like real skin, muscles and vessels

In the last 50 years, modern medicine has made astounding advances in surgery, yet many of today's veterinary and human medicine students still hone basic surgical and suturing skills on carpet pads and pig's feet before transitioning to a live patient. An invention by Colorado State University veterinarians provides students with artificial body parts that look, feel, behave, and even bleed just like real skin, muscles and vessels.

20 Nov 2010

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced the presentation of interim results from the first-in-human clinical study of ACE-041 in patients with advanced cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

20 Nov 2010

UNICEF report identifies factors helping, hindering efforts to drive down FGM/C in five African countries

A report released on Thursday by UNICEF highlights the recent progress made in reducing the practice of female genital mutilation/cutting (FGM/C) despite ongoing social pressures to continue the practice in five African countries, Deutsche Presse-Agentur/M&C reports (11/18).

19 Nov 2010

Bristol-Myers Squibb, Pfizer discontinue Phase 3 APPRAISE-2 trial in patients with ACS

Bristol-Myers Squibb Company and Pfizer today reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with recent Acute Coronary Syndrome (ACS) treated with apixaban or placebo in addition to mono or dual antiplatelet therapy.

19 Nov 2010

Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A

Ipsen announced today that its partner Inspiration Biopharmaceuticals, Inc. has initiated treatment of patients in the first of two phase III pivotal clinical studies of OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product, for the treatment of acquired hemophilia A, a rare, though potentially life-threatening bleeding disorder.

19 Nov 2010

Ethicon submits BLA to FDA for Fibrin Pad

Ethicon, Inc., a worldwide leader in surgical care, announced today that the company has submitted a Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the Fibrin Pad, a novel product candidate that combines Ethicon's biomaterials and plasma-derived biologics (Human Fibrinogen and Human Thrombin), to aid in stopping soft tissue bleeding during surgery.

19 Nov 2010

ESWL should be first choice for removing smaller kidney stones in distal ureter

Different techniques should be used to remove single stones that have become lodged in the distal ureter after being expelled by the kidney, depending on whether they are under or above one centimetre, according to the December issue of BJUI.

18 Nov 2010

Scientists solve structure of key protein from Lassa virus

Scientists at Emory University and the University of St. Andrews have solved the structure of a key protein from Lassa virus, which is endemic to West Africa and can cause a deadly hemorrhagic fever.

18 Nov 2010

Warfarin taken along with herbal, dietary supplements may be dangerous

Herbal and dietary supplements are popular. People claim they make their joints feel better, their bones stronger, and their hearts healthier. But a recent study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City shows that many of these people may not realize their favorite supplement, mixed with prescription medications, may be putting their lives in danger, especially if they are taking warfarin - a blood-thinning medication commonly prescribed to patients living with atrial fibrillation to lower their risk of stroke.

17 Nov 2010

Active management of third stage of labour leads to less blood loss

Active management of the third stage of labour means that women lose less blood than with a more expectant approach, reveals a thesis from the University of Gothenburg, Sweden, in conjunction with Sahlgrenska University Hospital.

17 Nov 2010

TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients

New results from an observational substudy from TRITON–TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with Efient/Effient (prasugrel) prior to coronary artery bypass graft surgery (CABG) had a reduced overall mortality rate compared to patients treated with Plavix (clopidogrel)

17 Nov 2010

One in seven Medicare patients harmed by problems in hospital, HHS report finds

The New York Times: "One of every seven Medicare beneficiaries who is hospitalized is harmed as a result of problems with the medical care there, according to a new study [.pdf] from the Office of Inspector General for the Department of Health and Human Services. The study said unexpected adverse events added at least $4.4 billion a year to government health costs and contributed to the deaths of about 180,000 patients a year."

17 Nov 2010

Anti-stroke blood thinner shows promise in large clinical trials

In new and extensive clinical trials an experimental blood thinner called rivaroxaban is at least as good at preventing strokes as the drug warfarin – that has been the most widely used agent for the past five decades in people with erratic heartbeats called atrial fibrillations. Researchers said this Monday that this drug also sharply reduces the risk of major bleeding that is seen with warfarin.

16 Nov 2010

Iron in plaque may predict risk of myocardial infarction

Plaque in a heart artery looks threatening, but cardiologists know that many of these buildups will not erupt, dislodge and block a vessel, causing a heart attack that can be fatal. Some will, however, and the challenge is to figure out atherosclerotic plaque that is dangerous and treat or remove it.

16 Nov 2010

Children's Hospital pediatric immunologist collaborates with European gene therapy researchers to study WAS syndrome

A pediatric immunologist at The Children's Hospital of Philadelphia collaborated with European gene therapy researchers who achieved marked clinical improvements in two young children with Wiskott-Aldrich syndrome, a very rare but often severe immunodeficiency disorder.

16 Nov 2010

Bayer presents results from Phase III ROCKET AF trial for atrial fibrillation at American Heart Association

Bayer today announced the results from the pivotal, double-blind Phase III, ROCKET AF trial. In the study, rivaroxaban demonstrated superiority to warfarin in reducing the risk of stroke and non-CNS systemic embolism in patients with atrial fibrillation (AF).

16 Nov 2010

PolyMedix presents data on PMX-60056 Phase 1B/2 studies for blood clotting at American Heart Association

PolyMedix, Inc, an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that data from two Phase 1B/2 clinical studies with PMX-60056 were presented today, in oral and poster sessions, at the Annual American Heart Association Scientific Sessions Meeting. PMX-60056 is a synthetic, small-molecule designed to reverse the anti-clotting effects of both heparin and low molecule weight heparin (LMWH).

16 Nov 2010

Emerging blood thinners to prevent stroke

As blood thinners emerge in the market for stroke prevention many experts believe is still too early to predict how they will stack up in the $15 billion a year market.

15 Nov 2010

Bleeding News and Research

GFAP levels predict brain injury, death in critically ill children on ECMO

Military surgeons provide guidance on handling emergency blast injuries

CSU invents artificial body parts that look, feel, behave, and bleed like real skin, muscles and vessels

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

UNICEF report identifies factors helping, hindering efforts to drive down FGM/C in five African countries

Bristol-Myers Squibb, Pfizer discontinue Phase 3 APPRAISE-2 trial in patients with ACS

Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A

Ethicon submits BLA to FDA for Fibrin Pad

ESWL should be first choice for removing smaller kidney stones in distal ureter

Scientists solve structure of key protein from Lassa virus

Warfarin taken along with herbal, dietary supplements may be dangerous

Active management of third stage of labour leads to less blood loss

TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients

One in seven Medicare patients harmed by problems in hospital, HHS report finds

Anti-stroke blood thinner shows promise in large clinical trials

Iron in plaque may predict risk of myocardial infarction

Children's Hospital pediatric immunologist collaborates with European gene therapy researchers to study WAS syndrome

Bayer presents results from Phase III ROCKET AF trial for atrial fibrillation at American Heart Association

PolyMedix presents data on PMX-60056 Phase 1B/2 studies for blood clotting at American Heart Association

Emerging blood thinners to prevent stroke

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News